UPDATE: Wedbush Upgrades Sequenom; Raises PT

According to a research report published his morning, Wedbush has upgraded Sequenom

from Underperform to Neutral, and increased PT from $3 to $5. In the report, Wedbush commented, " Upgrading to NEUTRAL from UNDERPERFORM to reflect MaterniT21 progress and limited near-term negative catalyst potential. SQNM has effectively met development and commercial launch milestones in the last 12 months and has driven significant test volume in the first six months of launch." Sequenom closed yesterday at $4.66.